These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 857076)

  • 1. Effects of high dialysate calcium concentration on bone remodelling, serum biochemistry, and parathyroid hormone in patients with renal osteodystrophy.
    Drüeke T; Bordier PJ; Man NK; Jungers P; Marie P
    Kidney Int; 1977 Apr; 11(4):267-74. PubMed ID: 857076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of dialysate calcium concentration on bone disease in patients on hemodialysis.
    Regan RJ; Peacock M; Rosen SM; Robinson PJ; Horsman A
    Kidney Int; 1976 Sep; 10(3):246-55. PubMed ID: 972445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intestinal calcium absorption, serum phosphate, and parathyroid hormone in patients with chronic renal failure and osteodystrophy before and during hemodialysis.
    Juttmann JR; Hagenouw-Taal JC; Lameyer LD; Ruis AM; Birkenhäger JC
    Calcif Tissue Res; 1978 Dec; 26(2):119-26. PubMed ID: 737558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between the serum parathyroid hormone and magnesium levels in continuous ambulatory peritoneal dialysis (CAPD) patients using low-magnesium peritoneal dialysate.
    Cho MS; Lee KS; Lee YK; Ma SK; Ko JH; Kim SW; Kim NH; Choi KC
    Korean J Intern Med; 2002 Jun; 17(2):114-21. PubMed ID: 12164088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlations and time course of FGF23 and markers of bone metabolism in maintenance hemodialysis patients.
    Bielesz BO; Hecking M; Plischke M; Cejka D; Kieweg H; Haas M; Marculescu R; Hörl WH; Bieglmayer C; Sunder-Plassmann G
    Clin Biochem; 2014 Sep; 47(13-14):1316-9. PubMed ID: 24956265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of CAPD and hemodialysis on parathyroid function.
    Malberti F; Corradi B; Imbasciati E
    Adv Perit Dial; 1996; 12():239-44. PubMed ID: 8865912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-calcium dialysate stimulates parathormone secretion and its long-term use worsens secondary hyperparathyroidism.
    Fernández E; Borràs M; Pais B; Montoliu J
    J Am Soc Nephrol; 1995 Jul; 6(1):132-5. PubMed ID: 7579066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Variations in serum levels of phosphorus (iP), calcium (Ca), calcitonin (iCT) and parathormone (iPTH) in patients under periodic hemodialysis. Effects of exogenous calcitonin therapy].
    Bucciante G; Bernardi A; Biasia F; Milan G; Donato D
    Minerva Med; 1985 Mar; 76(9-10):415-7. PubMed ID: 3982698
    [No Abstract]   [Full Text] [Related]  

  • 10. Combination therapy with sevelamer hydrochloride and calcium carbonate in Japanese patients with long-term hemodialysis: alternative approach for optimal mineral management.
    Ogata H; Koiwa F; Shishido K; Kinugasa E
    Ther Apher Dial; 2005 Feb; 9(1):11-5. PubMed ID: 15828900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of calcium and phosphorus in hemodialysis.
    Goldsmith RS
    Annu Rev Med; 1976; 27():181-90. PubMed ID: 180871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
    Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis.
    Chonchol M; Locatelli F; Abboud HE; Charytan C; de Francisco AL; Jolly S; Kaplan M; Roger SD; Sarkar S; Albizem MB; Mix TC; Kubo Y; Block GA
    Am J Kidney Dis; 2009 Feb; 53(2):197-207. PubMed ID: 19110359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pathogenesis of renal osteodystrophy: role of vitamin D, aluminium, parathyroid hormone, calcium and phosphorus.
    Dunstan CR; Hills E; Norman AW; Bishop JE; Mayer E; Wong SY; Johnson JR; George CR; Collett P; Kalowski S
    Q J Med; 1985 May; 55(217):127-44. PubMed ID: 4001311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal osteodystrophy in predialysis and hemodialysis patients: comparison of histologic patterns and diagnostic predictivity of intact PTH.
    Coen G; Ballanti P; Bonucci E; Calabria S; Costantini S; Ferrannini M; Giustini M; Giordano R; Nicolai G; Manni M; Sardella D; Taggi F
    Nephron; 2002 May; 91(1):103-11. PubMed ID: 12021526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute effect of pamidronate on PTH secretion in postmenopausal hemodialysis patients with secondary hyperparathyroidism.
    Lu KC; Yeung LK; Lin SH; Lin YF; Chu P
    Am J Kidney Dis; 2003 Dec; 42(6):1221-7. PubMed ID: 14655194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteocalcin, iPTH, alkaline phosphatase and hand X-ray scores as predictive indices of histomorphometric parameters in renal osteodystrophy.
    Mazzaferro S; Coen G; Ballanti P; Bondatti F; Bonucci E; Pasquali M; Sardella D; Tomei E; Taggi F
    Nephron; 1990; 56(3):261-6. PubMed ID: 2077408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Useful biochemical markers for diagnosing renal osteodystrophy in predialysis end-stage renal failure patients.
    Bervoets AR; Spasovski GB; Behets GJ; Dams G; Polenakovic MH; Zafirovska K; Van Hoof VO; De Broe ME; D'Haese PC
    Am J Kidney Dis; 2003 May; 41(5):997-1007. PubMed ID: 12722034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy.
    Massry SG; Goldstein DA; Malluche HH
    Kidney Int; 1980 Oct; 18(4):409-18. PubMed ID: 7014981
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical benefit of the change of dialysate calcium concentration from 3.0 to 2.75 mEq/L.
    Sakai Y; Otsuka T; Ohno D; Murasawa T; Sakai S; Tsuruoka S
    Ther Apher Dial; 2014 Apr; 18(2):181-4. PubMed ID: 24720409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.